银诺医药
INNOGEN

Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

ANNOUNCEMENT REGARDING THE POSTPONEMENT OF THE RE-ELECTION OF THE BOARD AND THE SUPERVISORY COMMITTEE

The terms of the first session of the board (the "**Board**") of directors (the "**Directors**") and the supervisory committee (the "**Supervisory Committee**") of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the "**Company**") will expire on 22 November 2025. Given that the preparation work for the re-election of the Board and the re-election of the Supervisory Committee (the "**Re-election**") is in progress, in order to maintain continued operations of the Board and the Supervisory Committee, the Re-election will be postponed, and the terms of the first session of the Board and the first session of the Supervisory Committee will be extended to the date when the new sessions of the Board and the Supervisory Committee are elected at the general meeting according to the articles of association of the Company. At the same time, the term of the first session of each board committee of the Company will be extended accordingly.

Before the completion of the Re-election, members of the first session of the Board, each board committee and the first session of the Supervisory Committee will continue to perform their respective duties in accordance with the relevant laws and regulations and the articles of association of the Company.

The postponement of the Re-election will not affect the normal operation of the Company. The Company shall proactively proceed with the Re-election and comply with the relevant requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and fulfill the corresponding disclosure obligations in a timely manner.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the PRC, 21 November 2025

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.